These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 19217455

  • 1. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M.
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [Abstract] [Full Text] [Related]

  • 2. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):170-6. PubMed ID: 19171131
    [Abstract] [Full Text] [Related]

  • 3. Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M.
    Horm Metab Res; 2008 Dec 01; 40(12):880-6. PubMed ID: 18819058
    [Abstract] [Full Text] [Related]

  • 4. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H.
    Life Sci; 2009 Jul 17; 85(3-4):122-6. PubMed ID: 19427871
    [Abstract] [Full Text] [Related]

  • 5. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacol Rep; 2009 Jul 17; 61(5):899-908. PubMed ID: 19904014
    [Abstract] [Full Text] [Related]

  • 6. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Nagase I, Hayakawa M, Shibasaki M.
    Biochem Pharmacol; 2008 Jul 01; 76(1):98-107. PubMed ID: 18468582
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacology; 2009 Jul 01; 83(3):177-87. PubMed ID: 19176982
    [Abstract] [Full Text] [Related]

  • 8. Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M.
    Basic Clin Pharmacol Toxicol; 2008 Dec 01; 103(6):560-8. PubMed ID: 18793271
    [Abstract] [Full Text] [Related]

  • 9. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
    Someya Y, Nakano R, Tahara A, Takasu T, Takeuchi A, Nagase I, Matsuyama-Yokono A, Hayakawa M, Sasamata M, Miyata K, Uchiyama Y.
    Eur J Pharmacol; 2009 Nov 10; 622(1-3):71-7. PubMed ID: 19766107
    [Abstract] [Full Text] [Related]

  • 10. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2006 Dec 10; 319(3):1253-7. PubMed ID: 16980568
    [Abstract] [Full Text] [Related]

  • 11. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S.
    Biochem Pharmacol; 2012 Jan 15; 83(2):241-52. PubMed ID: 22015634
    [Abstract] [Full Text] [Related]

  • 12. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Feb 15; 379(2):191-9. PubMed ID: 18762913
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ, Nian C, Doudet DJ, McIntosh CH.
    Diabetes; 2008 May 15; 57(5):1331-9. PubMed ID: 18299314
    [Abstract] [Full Text] [Related]

  • 14. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S.
    Int J Clin Pract Suppl; 2007 Aug 15; (154):38-48. PubMed ID: 17593276
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 15; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 16. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 15; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 17. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Eur J Pharmacol; 2008 Jul 07; 588(2-3):325-32. PubMed ID: 18499100
    [Abstract] [Full Text] [Related]

  • 18. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.
    J Pharmacol Exp Ther; 2005 Nov 07; 315(2):688-95. PubMed ID: 16027230
    [Abstract] [Full Text] [Related]

  • 19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.
    Diabetes Care; 2008 Jan 07; 31(1):30-5. PubMed ID: 17947341
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May 07; 377(3):209-17. PubMed ID: 18398600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.